期刊文献+

顺铂泡囊的研制与抗癌活性研究 被引量:1

Preparation of cis-diamminedichloroplatinum niosomes and its in vivo anti-tumor activity
原文传递
导出
摘要 目的:制备顺铂泡囊并对其进行理化性质和抗癌活性评价。方法:以Span40和胆固醇为主要材料制备泡囊,对其表面形态、粒径分布、电位、包封率、载药量及体外释放特性等理化性质进行考察,动物实验研究泡囊对荷VX2肉体瘤实验兔的体重变化、存活率、肿瘤生长和肿瘤细胞转移。结果:呈圆球状的泡囊粒径为(7.33±1.05)μm,包封率为(86.06±1.46)%,载药量为(3.04±0.05)%,体外释放实验t1/2在8 h附近。较之于市售制剂,存活率大大提高,毒性明显较小,更在抑制肿瘤生长和防止肿瘤细胞转移方面优势非常明显。结论:本实验研制的泡囊具有缓释作用和治疗肿瘤的高效低毒特点。 Objective: To prepare and characterize cis-diamminedichloroplatinum (CDDP) niosomes in vitro, and to evaluate their anti-tumor activity in vivo. Methods: The noisomes were prepared using Span40 and cholesterol as the main materials. Their morphology, particle size and distribution, electric potential, entrapment rate, drug-loading rate and release behavior in vitro were determined. Rabbits bearing VX2 sarcous tumor were sub- jected to anti-tumor tests, and the change in body weight, fraction surviving, tumor growth and cell metastasis were observed. Results : The diameter of the round-looking niosomes was (7.33 ± 1.05) μm. The entrapment rate was (86.06±1.46)%, and drug loading rate was (3.04 ±0.05)%. In vitro release tests gave a t1/2 of about 8 h. Compared with the marketed CDDP preparation, the niosomes increased surviving fraction and reduced toxicity in the tumor-bearing rabbits. Moreover, the niosomes showed obvious predominance in inhibition of tumor growth and cell metastasis. Conclusion: The prepared CDDP niosomes have sustained release behavior, higher anti-tumor activity and lower toxicity.
出处 《中国新药杂志》 CAS CSCD 北大核心 2009年第6期545-548,共4页 Chinese Journal of New Drugs
基金 国家自然科学基金资助项目(30572262)
关键词 顺铂 泡囊 缓释作用 存活率 抑制肿瘤生长 cis-diamminedichloroplatinum niosomes sustained release behavior fraction surviving inhibition of tumor growth
  • 相关文献

参考文献8

  • 1陈永,杨红,陆彬,李玫,宗太丽.肺靶向顺铂泡囊的研制与体外性质的评价[J].华西药学杂志,2008,23(2):129-132. 被引量:8
  • 2GRYPARIS EC, HATZIAPOSTOLOU M, PAPADIMITRIOU E, et al. Anticanccr activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells[ J]. Eur J Pharm Biopharm, 2007,67(1):1 -8.
  • 3HUO DJ,DENG SH,LI LB,et al. Studies on the poly(lactic-coglycolic) acid microspheres of cisplatin for lung-targeting[ J]. Int J Pharm,2005,289 (1-2) :63 - 67.
  • 4PELEG-SHULMAN T,GIBSON D,COHEN R,et al. Characterization of sterically stabilized eisplatin liposomes by nuclear magnetic resonance[J]. Biochim Biophys Acta, 2001, 1510 ( 1-2 ) : 278 -291
  • 5BONTHA S,KABANOV AV,BRONICH TK. Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs[ J]. J Control Release ,2006,114 ( 2 ) : 163 - 174.
  • 6FANG JY,YU SY,WU PC ,et al. In vitro skin permeation of estradiol from various proniosome formulation[ J ]. Int J Pharm,2001, 215(1-2) :91 -99.
  • 7YOSHIOKA T,STERNBERG B,FLORENCE AT. Preparation and properties of versicles (niosomes) of sorbitan monoesters ( span 20,40,60 and 80) and a sorbitan triester ( span 85 ) [ J]. Int J Pharm, 1994,105 ( 1 ) : 1 - 6.
  • 8LU B,ZHANG JQ,YANG H. Lung-targeting microspheres of carboplatin[ J]. Int J Pharm ,2003,265 ( 1-2 ) : 1 - 11.

二级参考文献8

共引文献7

同被引文献9

  • 1陈永,杨红,陆彬,李玫,宗太丽.肺靶向顺铂泡囊的研制与体外性质的评价[J].华西药学杂志,2008,23(2):129-132. 被引量:8
  • 2柯爱武,李羲.聚乙二醇修饰免疫脂质体研究进展[J].国外医学(预防.诊断.治疗用生物制品分册),2004,27(4):170-174. 被引量:7
  • 3BOSCH ME,SANCHEZ A J, ROJAS FS,et al. Analytical methodologies for the determination of cisplatim [ J ]. J Pharm Biomed Anal,2008,47 ( 3 ) :451 - 459.
  • 4JISKOOT W,HOVEN AMV,DE KONING AAM,et al. Purification and stabilization of a poorly soluble mouse IgG3 monoclonal antibody [ J ]. Immunological Methods, 1991,138 ( 1 ) : 181 - 189.
  • 5DEVARAJ GN,PARAKH SR,DEVRAJ R,et al. Release studies on niosomes containing fatty alcohols as bilayer stabilizers instead of cholesterol[J]. J Colloid Interface Sci, 2002,251 ( 2 ) : 360 - 365.
  • 6VANGALA A,BRAMWELL VW,MCNEIL S,et al. Comparison of vesicle based antigen delivery systems for delivery of hepatitis B surface antigen [ J ]. J Control Release ,2007,119 ( 1 ) : 102 - 110.
  • 7MOKHTAR M,SAMMOUR OA,HAMMAD MA,et al. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes [ J ]. Int J Pharm, 2008 : 361 ( 1-2 ) : 104 - 111.
  • 8GIANASI E,COCIANCICH F, UCHEGBU IF,et al. Pharmaceutical and biological characterisation of a doxorubicin-polymer conjugate (PKI) entrapped in sorbitan monostearate Span 60 niosomes[J], Int J Pharm,1997 ,148( 2 ) :139 -148.
  • 9许向阳,周建平,李玲,施丹霞,卢是玥,杨洁,霍美蓉.阿霉素高聚物胶束的制备及其体外抗肿瘤活性研究[J].中国药学杂志,2008,43(7):514-518. 被引量:9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部